DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00505778 (ClinicalTrials.gov)	July 2007	20/7/2007	A Comparison of Once a Day Dose Compared to 2 Doses/Day	A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis	Ulcerative Colitis	Drug: Mesalamine Once-Daily;Drug: Mesalamine Twice-Daily	Warner Chilcott	NULL	Completed	18 Years	N/A	All	1027	Phase 3	United States;Canada;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00505778
(ClinicalTrials.gov)

July 2007

20/7/2007

A Comparison of Once a Day Dose Compared to 2 Doses/Day

A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis

Ulcerative Colitis

Drug: Mesalamine Once-Daily;Drug: Mesalamine Twice-Daily

Warner Chilcott

NULL

Completed

18 Years

N/A

All

1027

Phase 3

United States;Canada;Puerto Rico